[1] |
GENG Qianqian, YANG Aimin.
Progress and prospect on treatment for radioiodine-refractory thyroid cancer
[J]. China Oncology, 2025, 35(1): 30-39.
|
[2] |
WANG Renfei, LU Gaixia.
The unique value and controversy of nuclear medicine molecular imaging in the evaluation of radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 49-57.
|
[3] |
LIN Qiuyu, WANG Yuxin, LIN Chenghe.
Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 58-67.
|
[4] |
JIANG Xiaotong, LIU Jinchuan, ZHANG Yingqiang, WANG Tong, GUO Ning, SUN Yuqing, SHI Cong, YAN Bing, LIN Yansong.
The role of diagnostic whole body scan in decision-making of 131I treatment for differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 77-84.
|
[5] |
PAN Yijin, SHI Cong, SUN Yuqing, SUN Di, ZHAO Yihan, ZHANG Jin, LIN Yansong.
Global trends of 131I-therapy for differentiated thyroid cancer in children and adolescents: a bibliometric analysis (1993-2003)
[J]. China Oncology, 2024, 34(12): 1123-1133.
|
[6] |
DENG Shuting, FENG Yuan, QIAN Kai, GUO Kai, WANG Zhuoying.
Meta-analysis of the association between gene alterations and distant metastasis of differentiated thyroid carcinoma in children and adolescents
[J]. China Oncology, 2022, 32(5): 388-396.
|
[7] |
GUO Wenting, MU Zhuanzhuan, LI Zheng, ZHANG Yingqiang, JIN Xiaona, LIN Yansong.
Clinical outcome of 131I therapy in differentiated thyroid cancer patients with suspicious high thyroglobulin concentration
[J]. China Oncology, 2022, 32(5): 410-416.
|
[8] |
MEI Xiaoran, FENG Fang, WANG Hui, WEI Zhixiao.
Analysis of therapeutic response of iodine positive metastasis lymph nodes in differentiated thyroid cancer after 131I treatment
[J]. China Oncology, 2022, 32(11): 1091-1097.
|
[9] |
LI Min, WEN Peng, QIAN Qiuqin, QIN Ang, ZENG Li, SHI Feng.
Clinical study of iodine-125 seeds implantation in the treatment of lymph node metastasis of radioactive iodine- refractory differentiated thyroid cancer
[J]. China Oncology, 2020, 30(2): 122-127.
|
[10] |
ZHANG Na, LIN Yansong, LIANG Jun.
The clinical significance of thyroglobulin antibody measurement in 131I therapy of differentiated thyroid carcinoma
[J]. China Oncology, 2019, 29(6): 452-456.
|
[11] |
GAO Luying, LIN Yansong, JIANG Yuxin, LI Jianchu, LI Hui, ZHANG Bo, LIU Ruyu, XI Xuehua, GAO Qiong, WANG Ying, ZHAO Ruina.
Evaluation of short-term efficacy of apatinib using cervical ultrasound and thyroglobulin in the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2019, 29(6): 418-422.
|
[12] |
ZHANG Liyang, LIU Chunhao, CAO Yue, LIU Hongfeng, GAO Weisheng, LI Xiaoyi.
Experiences of 125 cases of re-operated persistent/recurrent differentiated thyroid cancer
[J]. China Oncology, 2019, 29(6): 412-417.
|
[13] |
YANG Ke, ZHENG Rong, LIN Yansong.
The interpretation of management guidelines for children with thyroid nodules and differentiated thyroid cancer: radioactive iodine therapy and new progress
[J]. China Oncology, 2019, 29(6): 401-411.
|
[14] |
SONG Juanjuan, LIU Yanqing, LIN Yansong.
Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose 131I therapy
[J]. China Oncology, 2019, 29(3): 207-211.
|
[15] |
ZHANG Yingqiang, ZHANG Xin, WANG Chen, et al.
The value of 18F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy
[J]. China Oncology, 2018, 28(7): 505-510.
|